Vimarsana
Biggest News Aggregation in the World

Page 11 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis - Vimarsana News

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis - Vimarsana News

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...

Innovis Asset Management LLC Purchases Shares of 80,773 Immunic, Inc. (NASDAQ:IMUX) - Vimarsana News

Innovis Asset Management LLC Purchases Shares of 80,773 Immunic, Inc. (NASDAQ:IMUX)

Innovis Asset Management LLC purchased a new stake in Immunic, Inc. (NASDAQ:IMUX – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 80,773 shares of the company’s stock, valued at approximately $120,000. Innovis Asset Management LLC owned 0.18% […]

Immunic (NASDAQ:IMUX) Rating Reiterated by Wedbush - Vimarsana News

Immunic (NASDAQ:IMUX) Rating Reiterated by Wedbush

Wedbush restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com started coverage on Immunic in a research note on Thursday, May 18th. They issued a sell rating on the stock. […]

Source: wkrb13.com
Immunic (NASDAQ:IMUX) Receives Outperform Rating from Wedbush - Vimarsana News

Immunic (NASDAQ:IMUX) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday morning, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com initiated coverage on Immunic in a research report on Thursday, May 18th. They set a sell rating on the […]